Enhancement of cerebral diseases: How much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T

被引:20
作者
Brekenfeld, C
Foert, E
Hundt, W
Kenn, W
Lodeann, KP
Gehl, HB
机构
[1] Med Univ Lubeck, Dept Radiol, D-23538 Lubeck, Germany
[2] Univ Klinikum Steglitz, Dept Radiol, Berlin, Germany
[3] Univ Munich, Klinikum Grosshadern, Dept Radiol, D-8000 Munich, Germany
[4] Med Univ Wurzburg, Dept Radiol, Wurzburg, Germany
[5] Bracco Byk Gulden, Constance, Germany
关键词
contrast media; MRI; brain lesions; low-field MRI;
D O I
10.1097/00004424-200105000-00004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
RATIONALE AND OBJECTIVES. TO determine the clinical dose of gadoteridol (ProHance, Bracco-Byk Gulden) to use for the assessment of blood-brain barrier breakdown on low-field magnetic resonance (MR) scanners that corresponds to a standard dose of gadoteridol on high-field MR scanners. METHODS. This prospective study was carried out at four centers. A total of 138 patients with suspected or known brain diseases underwent a routine head scan comprising precontrast T2-weighted turbo spin-echo and T1-weighted spin-echo sequences on a 1.5-T MR scanner. After administration of a standard dose of 0.1 mmol/kg gadoteridol, the T1-weighted scan was repeated after a delay of 15 to 20 minutes, For continuing the examination on a 0.2-T MR scanner (Magnetom OPEN, Siemens), a standard-dose T1 spin-echo sequence was started within 30 to 50 minutes of the first injection. Then two additional T1-weighted low-field sequences were each started 5 minutes after two additional doses of 0.1 mmol/kg gadoteridol, Eighty patients with enhancing lesions underwent an intraindividual comparison. Evaluation of the overall numbers of lesions detected and of lesion size and character was performed on-site as well as off-site by two independent readers. RESULTS. The single-dose, low-field sequence detected significantly fewer enhancing lesions (80/95 lesions; P < 0.05), particularly metastases and infarctions, than did the standard-dose, high-field sequence. No statistically relevant differences (reader 1: P = 1; reader 2: P = 0.8) were found between the double- and triple-dose, low-field sequences and the standard-dose, high-field sequence. Primary brain tumors were detected by all postcontrast sequences irrespective of the dose. CONCLUSIONS. At low field, the clinically equivalent dose to 0.1 mmol/kg gadoteridol at high field is 0.2 mmol/kg, A dose of 0.1 mmol/kg gadoteridol is less effective and cannot be recommended for use on extremely low-field scanners.
引用
收藏
页码:266 / 275
页数:10
相关论文
共 21 条
[1]  
CHANG KH, 1994, AM J NEURORADIOL, V15, P1413
[2]   MAGNETIC-RESONANCE IMAGING - EFFECTS OF MAGNETIC-FIELD STRENGTH [J].
CROOKS, LE ;
ARAKAWA, M ;
HOENNINGER, J ;
MCCARTEN, B ;
WATTS, J ;
KAUFMAN, L .
RADIOLOGY, 1984, 151 (01) :127-133
[3]  
DAVIS PC, 1991, AM J ROENTGENOL, V156, P1039
[4]  
Elster A D, 1997, Eur Radiol, V7 Suppl 5, P276
[5]   BRAIN-TUMORS - MR IMAGING WITH GADOLINIUM-DTPA [J].
FELIX, R ;
SCHORNER, W ;
LANIADO, M ;
NIENDORF, HP ;
CLAUSSEN, C ;
FIEGLER, W ;
SPECK, U .
RADIOLOGY, 1985, 156 (03) :681-688
[6]  
HAUSTEIN J, 1992, AM J NEURORADIOL, V13, P1199
[7]   INCREASED DETECTION OF INTRACRANIAL METASTASES WITH INTRAVENOUS GD-DTPA [J].
HEALY, ME ;
HESSELINK, JR ;
PRESS, GA ;
MIDDLETON, MS .
RADIOLOGY, 1987, 165 (03) :619-624
[8]  
KORMANO M, 1988, INVEST RADIOL, V23, P289
[9]   Safety and efficiency of Gadobutrol in patients with cerebral tumours (phase 3 trial) [J].
Lemke, AJ ;
Sander, B ;
Balzer, T ;
Geens, V ;
Hosten, N ;
Felix, R .
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 1997, 167 (06) :591-598
[10]  
LINDSEY RO, 1994, AM J NEURORADIOL, V15, P1849